Chaffanjon P C, Brichon P Y, Ranchoup Y, Gressin R, Sotto J J
Service de Chirurgie Générale et Thoracique, Centre Hospitalier et Universitaire de Grenoble, France.
World J Surg. 1998 Oct;22(10):1082-6. doi: 10.1007/s002689900521.
We report the results of a prospective series of 60 consecutive splenectomies for hematologic disorders performed between February 1995 and May 1996. The portal venous flow of all the patients (34 men and 26 women with a mean age of 54.1 years) was systematically studied before and after intervention with Doppler color imaging (on the day before the intervention and on the 7th and 30th postoperative days). The objective of this study were to determine the real frequency of asymptomatic portal or splenic venous thrombosis (PSVT) after hematologic splenectomy. The intervention began with exteriorization of the spleen and the tail of the pancreas; ligation of the splenic vein was performed close to its junction with the inferior mesenteric vein. Twenty-three complications (38.3%) were noted with three deaths (5%). One symptomatic PSVT (1.6%) and three asymptomatic PSVTs (6.7%) were diagnosed and treated with no deaths. Three risk factors of PSVT, recognized by all the authors, were present in these four cases: large splenomegaly, thrombocytosis, or myeloproliferative disorder. The systematic ultrasonographic (US) examinations increased the frequency of diagnosis of PSVT sevenfold during the perioperative period. Patients with marked splenomegaly associated with lymphoma, chronic lymphocytic leukemia, or myeloid metaplasia probably require systematic US monitoring during follow-up, but this must be determined by further study.
我们报告了1995年2月至1996年5月期间连续进行的60例因血液系统疾病行脾切除术的前瞻性系列研究结果。对所有患者(34例男性和26例女性,平均年龄54.1岁)在干预前后(干预前一天、术后第7天和第30天)采用彩色多普勒成像系统研究门静脉血流情况。本研究的目的是确定血液系统疾病脾切除术后无症状门静脉或脾静脉血栓形成(PSVT)的实际发生率。手术从显露脾脏和胰尾开始;在脾静脉与肠系膜下静脉交界处附近结扎脾静脉。记录到23例并发症(38.3%),3例死亡(5%)。诊断出1例有症状的PSVT(1.6%)和3例无症状的PSVT(6.7%),均接受治疗,无死亡病例。这4例患者均存在所有作者公认的PSVT的3个危险因素:脾肿大、血小板增多症或骨髓增殖性疾病。系统性超声(US)检查使围手术期PSVT的诊断率提高了7倍。伴有淋巴瘤、慢性淋巴细胞白血病或骨髓化生的明显脾肿大患者在随访期间可能需要系统性US监测,但这必须通过进一步研究来确定。